Identification of Molecular Determinants in iRhoms1 and 2 That Contribute to the Substrate Selectivity of Stimulated ADAM17.

ADAM17 (a disintegrin and metalloprotease 17) EGFR-ligand (epidermal growth factor receptor ligand) iRhom1 and 2 (inactive rhomboid like protein 1 and 2) protein ectodomain shedding

Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
24 Oct 2022
Historique:
received: 07 09 2022
revised: 03 10 2022
accepted: 19 10 2022
entrez: 11 11 2022
pubmed: 12 11 2022
medline: 15 11 2022
Statut: epublish

Résumé

The metalloprotease ADAM17 is a key regulator of the TNFα, IL-6R and EGFR signaling pathways. The maturation and function of ADAM17 is controlled by the seven-membrane-spanning proteins iRhoms1 and 2. The functional properties of the ADAM17/iRhom1 and ADAM17/iRhom2 complexes differ, in that stimulated shedding of most ADAM17 substrates tested to date can be supported by iRhom2, whereas iRhom1 can only support stimulated shedding of very few ADAM17 substrates, such as TGFα. The first transmembrane domain (TMD1) of iRhom2 and the sole TMD of ADAM17 are important for the stimulated shedding of ADAM17 substrates by iRhom2. However, little is currently known about how the iRhoms interact with different substrates to control their stimulated shedding by ADAM17. To provide new insights into this topic, we tested how various chimeras between iRhom1 and iRhom2 affect the stimulated processing of the EGFR-ligands TGFα (iRhom1- or 2-dependent) and EREG (iRhom2-selective) by ADAM17. This uncovered an important role for the TMD7 of the iRhoms in determining their substrate selectivity. Computational methods utilized to characterize the iRhom1/2/substrate interactions suggest that the substrate selectivity is determined, at least in part, by a distinct accessibility of the substrate cleavage site to stimulated ADAM17. These studies not only provide new insights into why the substrate selectivity of stimulated iRhom2/ADAM17 differs from that of iRhom1/ADAM17, but also suggest new approaches for targeting the release of specific ADAM17 substrates.

Identifiants

pubmed: 36361585
pii: ijms232112796
doi: 10.3390/ijms232112796
pmc: PMC9654401
pii:
doi:

Substances chimiques

Transforming Growth Factor alpha 0
Carrier Proteins 0
ADAM17 Protein EC 3.4.24.86
Membrane Proteins 0
ErbB Receptors EC 2.7.10.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIGMS NIH HHS
ID : R35 GM134907
Pays : United States
Organisme : NIH HHS
ID : NIGMS R35 GM134907
Pays : United States
Organisme : NIH HHS
ID : NIGMS T32GM007739
Pays : United States

Références

Nature. 1997 Feb 20;385(6618):729-33
pubmed: 9034190
Exp Cell Res. 2003 Mar 10;284(1):2-13
pubmed: 12648462
J Clin Invest. 2013 Feb;123(2):928-32
pubmed: 23348744
PLoS One. 2013;8(1):e54853
pubmed: 23349978
Sci Transl Med. 2019 May 8;11(491):
pubmed: 31068444
Science. 2012 Jan 13;335(6065):229-32
pubmed: 22246778
J Cell Sci. 2017 Mar 1;130(5):868-878
pubmed: 28104813
FASEB J. 2020 Apr;34(4):4956-4969
pubmed: 32103528
N Engl J Med. 2011 Oct 20;365(16):1502-8
pubmed: 22010916
Pharmacol Res. 2013 May;71:19-22
pubmed: 23415892
Nat Methods. 2017 Jan;14(1):71-73
pubmed: 27819658
EMBO Rep. 2013 Oct;14(10):884-90
pubmed: 23969955
Expert Opin Ther Targets. 2012 Jan;16(1):15-31
pubmed: 22239438
JCI Insight. 2022 Sep 22;7(18):
pubmed: 35998057
Science. 2012 Jan 13;335(6065):225-8
pubmed: 22246777
Cell Rep. 2017 Oct 17;21(3):745-757
pubmed: 29045841
Nature. 1997 Feb 20;385(6618):733-6
pubmed: 9034191
Mol Cell Biol. 2013 Aug;33(16):3077-90
pubmed: 23732913
Sci Rep. 2021 May 5;11(1):9552
pubmed: 33953303
J Am Chem Soc. 2014 Nov 12;136(45):16044-54
pubmed: 25314362
Elife. 2018 Jun 13;7:
pubmed: 29897333
J Cell Sci. 2007 Mar 15;120(Pt 6):943-52
pubmed: 17344430
J Cell Sci. 2010 Nov 15;123(Pt 22):3913-22
pubmed: 20980382
Cell. 2017 Dec 14;171(7):1638-1648.e7
pubmed: 29224781
Cells. 2022 Aug 29;11(17):
pubmed: 36078095
Oncotarget. 2016 Aug 23;7(34):55890-55899
pubmed: 27344184
Int J Mol Sci. 2020 Nov 19;21(22):
pubmed: 33227998
Hum Pathol. 2015 Jun;46(6):923-8
pubmed: 25804906
J Immunol. 2007 Sep 1;179(5):2686-9
pubmed: 17709479
J Biol Chem. 2021 Jan-Jun;296:100733
pubmed: 33957124
Biochem Biophys Res Commun. 2003 Aug 22;308(2):331-8
pubmed: 12901873
Nat Rev Drug Discov. 2018 Jun;17(6):395-412
pubmed: 29725131
J Comput Chem. 2005 Dec;26(16):1781-802
pubmed: 16222654
Nature. 2021 Aug;596(7873):583-589
pubmed: 34265844
Nucleic Acids Res. 2022 Jan 7;50(D1):D439-D444
pubmed: 34791371
Biochim Biophys Acta Mol Cell Res. 2017 Nov;1864(11 Pt B):2059-2070
pubmed: 28705384
Biochim Biophys Acta. 2011 Dec;1816(2):119-31
pubmed: 21658434
Sci Transl Med. 2013 Aug 21;5(199):199ra111
pubmed: 23966300
J Biol Chem. 2002 Apr 12;277(15):12838-45
pubmed: 11823465
ACS Chem Neurosci. 2019 Nov 20;10(11):4579-4592
pubmed: 31553164
ACS Chem Neurosci. 2021 Feb 17;12(4):651-659
pubmed: 33507062
J Comput Chem. 2010 Jan 30;31(2):455-61
pubmed: 19499576
Methods Mol Biol. 2006;327:99-113
pubmed: 16780215
Science. 1998 Nov 13;282(5392):1281-4
pubmed: 9812885
J Cell Biol. 2004 Mar 1;164(5):769-79
pubmed: 14993236
Biochem Soc Symp. 2003;(70):39-52
pubmed: 14587281
Immunity. 2015 Feb 17;42(2):216-226
pubmed: 25692699
Mol Oncol. 2018 Jan;12(1):3-20
pubmed: 29124875
Front Pharmacol. 2022 Aug 09;13:945935
pubmed: 36016551
J Exp Med. 2012 Jun 4;209(6):1105-19
pubmed: 22565824
J Exp Med. 2010 Aug 2;207(8):1617-24
pubmed: 20603312
Nat Rev Mol Cell Biol. 2005 Jan;6(1):32-43
pubmed: 15688065
Development. 2003 Oct;130(19):4515-25
pubmed: 12925580
Proc Natl Acad Sci U S A. 2015 May 12;112(19):6080-5
pubmed: 25918388
Proc Natl Acad Sci U S A. 2013 Jul 9;110(28):11433-8
pubmed: 23801765
Int J Mol Sci. 2021 Nov 27;22(23):
pubmed: 34884633
Elife. 2018 Jun 13;7:
pubmed: 29897336
Elife. 2017 Apr 22;6:
pubmed: 28432785

Auteurs

Yi Zhao (Y)

Department of Biochemistry, Cellular and Molecular Biology, Weill Cornell Medicine, New York, NY 10021, USA.

Eliud Morales Dávila (EM)

School of Chemical Sciences, Meritorious Autonomous University of Puebla (BUAP), University City, Puebla 72570, Mexico.

Xue Li (X)

Department of Biochemistry, Cellular and Molecular Biology, Weill Cornell Medicine, New York, NY 10021, USA.

Beiyu Tang (B)

Department of Pharmacology, Weill Cornell Medicine, New York, NY 10021, USA.

Ariana I Rabinowitsch (AI)

Department of Biochemistry, Cellular and Molecular Biology, Weill Cornell Medicine, New York, NY 10021, USA.
Weill Cornell/Rockefeller/Sloan-Kettering Tri-Institutional MD-PhD Program, New York, NY 10021, USA.

Jose Manuel Perez-Aguilar (JM)

School of Chemical Sciences, Meritorious Autonomous University of Puebla (BUAP), University City, Puebla 72570, Mexico.

Carl P Blobel (CP)

Department of Physiology, Biophysics and Systems Biology, Weill Cornell Medicine, New York, NY 10021, USA.
Arthritis and Tissue Degeneration Program, Hospital for Special Surgery, New York, NY 10021, USA.

Articles similaires

The FGF/FGFR/c-Myc axis as a promising therapeutic target in multiple myeloma.

Arianna Giacomini, Sara Taranto, Giorgia Gazzaroli et al.
1.00
Humans Multiple Myeloma Receptors, Fibroblast Growth Factor Fibroblast Growth Factors Proto-Oncogene Proteins c-myc
Animals Humans Sarcomeres Muscle Proteins Carrier Proteins
Animals Lung India Sheep Transcriptome

Calcineurin inhibition enhances

Priyanka Das, Alejandro Aballay, Jogender Singh
1.00
Animals Caenorhabditis elegans Longevity Caenorhabditis elegans Proteins Calcineurin

Classifications MeSH